Literature DB >> 15241631

Fluorinated tracers for imaging cancer with positron emission tomography.

Olivier Couturier1, André Luxen, Jean-François Chatal, Jean-Philippe Vuillez, Pierre Rigo, Roland Hustinx.   

Abstract

2-[18F]fluoro-2-deoxy-D-glucose (FDG) is currently the only fluorinated tracer used in routine clinical positron emission tomography (PET). Fluorine-18 is considered the ideal radioisotope for PET imaging owing to the low positron energy (0.64 MeV), which not only limits the dose rate to the patient but also results in a relatively short range of emission in tissue, thereby providing high-resolution images. Further, the 110-min physical half-life allows for high-yield radiosynthesis, transport from the production site to the imaging site and imaging protocols that may span hours, which permits dynamic studies and assessment of potentially fairly slow metabolic processes. The synthesis of fluorinated tracers as an alternative to FDG was initially tested using nucleophilic fluorination of the molecule, as performed when radiolabelling with iodine-124 or bromide-76. However, in addition to being long, with multiple steps, this procedure is not recommended for bioactive molecules containing reactive groups such as amine or thiol groups. Radiochemical yields are also often low. More recently, radiosynthesis from prosthetic group precursors, which allows easier radiolabelling of biomolecules, has led to the development of numerous fluorinated tracers. Given the wide availability of 18F, such tracers may well develop into important routine tracers. This article is a review of the literature concerning fluorinated radiotracers recently developed and under investigation for possible PET imaging in cancer patients. Two groups can be distinguished. The first includes "generalist" tracers, i.e. tracers amenable to use in a wide variety of tumours and indications, very similar in this respect to FDG. These are tracers for non-specific cell metabolism, such as protein synthesis, amino acid transport, nucleic acid synthesis or membrane component synthesis. The second group consists of "specific" tracers for receptor expression (i.e. oestrogens or somatostatin), cell hypoxia or bone metabolism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15241631     DOI: 10.1007/s00259-004-1607-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  271 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose.

Authors:  F Dehdashti; B A Siegel; L K Griffeth; M J Fusselman; D D Trask; A H McGuire; D J McGuire
Journal:  Radiology       Date:  1996-07       Impact factor: 11.105

3.  Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by positron emission tomography.

Authors:  A Liu; K E Carlson; J A Katzenellenbogen
Journal:  J Med Chem       Date:  1992-05-29       Impact factor: 7.446

4.  Whole-body skeletal imaging in mice utilizing microPET: optimization of reproducibility and applications in animal models of bone disease.

Authors:  Frank Berger; Yu-Po Lee; Andreas M Loening; Arion Chatziioannou; Stephen J Freedland; Richard Leahy; Jay R Lieberman; Arie S Belldegrun; Charles L Sawyers; Sanjiv S Gambhir
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-09       Impact factor: 9.236

5.  Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck.

Authors:  M Nordsmark; M Overgaard; J Overgaard
Journal:  Radiother Oncol       Date:  1996-10       Impact factor: 6.280

6.  Selective 2-[18F]fluorodopa uptake for melanogenesis in murine metastatic melanomas.

Authors:  K Ishiwata; K Kubota; R Kubota; R Iwata; T Takahashi; T Ido
Journal:  J Nucl Med       Date:  1991-01       Impact factor: 10.057

7.  Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy.

Authors:  Beatrice M Seddon; Ross J Maxwell; Davina J Honess; Rachel Grimshaw; Florence Raynaud; Gillian M Tozer; Paul Workman
Journal:  Clin Cancer Res       Date:  2002-07       Impact factor: 12.531

8.  Early changes in [18F]FLT uptake after chemotherapy: an experimental study.

Authors:  Helmut Dittmann; Bernhard Matthias Dohmen; Rainer Kehlbach; Gabi Bartusek; Maren Pritzkow; Mario Sarbia; Roland Bares
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-09-06       Impact factor: 9.236

9.  3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules.

Authors:  Andreas K Buck; Holger Schirrmeister; Martin Hetzel; Mareike Von Der Heide; Gisela Halter; Gerhard Glatting; Torsten Mattfeldt; Florian Liewald; Sven N Reske; Bernd Neumaier
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

10.  A marker for hypoxic cells in tumours with potential clinical applicability.

Authors:  J D Chapman; A J Franko; J Sharplin
Journal:  Br J Cancer       Date:  1981-04       Impact factor: 7.640

View more
  17 in total

1.  A plea for the elective inclusion of the brain in routine whole-body FDG PET.

Authors:  Tarik Belhocine; Stefan Markus Weiner; Ingo Brink; Peter Paul De Deyn; Jan Roland; Thierry Van der Borght; Patrick Flamen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03       Impact factor: 9.236

2.  Which radionuclides will nuclear oncology need tomorrow?

Authors:  Jacques Barbet; Jean-François Chatal; François Gauché; Jacques Martino
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06       Impact factor: 9.236

3.  Microwave-induced nucleophilic [18F]fluorination on aromatic rings: synthesis and effect of halogen on [18F]fluoride substitution of meta-halo (F, Cl, Br, I)-benzonitrile derivatives.

Authors:  Ning Guo; David Alagille; Gilles Tamagnan; Ronald R Price; Ronald M Baldwin
Journal:  Appl Radiat Isot       Date:  2008-03-10       Impact factor: 1.513

4.  Synthesis, uptake mechanism characterization and biological evaluation of (18)F labeled fluoroalkyl phenylalanine analogs as potential PET imaging agents.

Authors:  Limin Wang; Wenchao Qu; Brian P Lieberman; Karl Plössl; Hank F Kung
Journal:  Nucl Med Biol       Date:  2011-01       Impact factor: 2.408

Review 5.  Metabolic positron emission tomography imaging in cancer detection and therapy response.

Authors:  Aizhi Zhu; Daniel Lee; Hyunsuk Shim
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

Review 6.  Fluorinated porphyrinoids as efficient platforms for new photonic materials, sensors, and therapeutics.

Authors:  N V S Dinesh K Bhupathiraju; Waqar Rizvi; James D Batteas; Charles Michael Drain
Journal:  Org Biomol Chem       Date:  2016-01-14       Impact factor: 3.876

7.  Fluoride-Promoted Ligand Exchange in Diaryliodonium Salts.

Authors:  Bijia Wang; Ronald L Cerny; Shriharsha Uppaluri; Jayson J Kempinger; Stephen G Dimagno
Journal:  J Fluor Chem       Date:  2010-11-01       Impact factor: 2.050

Review 8.  Targeted nanoagents for the detection of cancers.

Authors:  Jason R McCarthy; Jayeeta Bhaumik; Mark R Karver; S Sibel Erdem; Ralph Weissleder
Journal:  Mol Oncol       Date:  2010-09-08       Impact factor: 6.603

Review 9.  Multimodality imaging: an update on PET/CT technology.

Authors:  Osama Mawlawi; David W Townsend
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

Review 10.  Current molecular imaging positron emitting radiotracers in oncology.

Authors:  Aizhi Zhu; Hyunsuk Shim
Journal:  Nucl Med Mol Imaging       Date:  2011-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.